What is EMA Policy 70?: Unlocking transparency in medicine

Chris Smith Date published: Feb 14, 24

The European Medicines Agency (EMA) plays an important role in ensuring the safety and efficacy of medicines. As demands for transparency in clinical trials and medical data grow, the EMA has responded with innovative policies. One such milestone is EMA Policy 70. It’s officially known as the European Medicines Agency policy on the publication of clinical data for medicinal products intended for human use.

The objectives of EMA Policy 70

EMA Policy 70 is based on three main goals: To protect and promote public health by providing a better understanding of the clinical data behind regulatory decisions; to increase transparency so that stakeholders can access important information about medicines and to respond to the growing need for transparency by ensuring that regulatory decisions are based on sound clinical evidence.

Protecting and fostering public health

The primary objective of EMA Policy 70 is to safeguard and nurture public health. By making the clinical data associated with regulatory decisions more accessible, the policy aims to empower the public with a comprehensive understanding of the safety and efficacy of medicinal products. This transparency contributes to informed decision-making by healthcare professionals, patients and the general public. Ultimately, the goal is to ensure that regulatory actions prioritize and positively impact public health outcomes.

Enhancing transparency in medicinal products

A key focus of EMA Policy 70 is to enhance transparency in the realm of medicinal products. This involves providing stakeholders, including healthcare professionals, researchers and patients, with unrestricted access to clinical information about the development and evaluation of medicines. By allowing a deeper insight into clinical data, the policy fosters trust and accountability within the healthcare system. Stakeholders can assess the evidence supporting regulatory decisions, leading to a more transparent and collaborative healthcare environment.

Meeting the increasing demand for transparency

EMA Policy 70 is a responsive measure addressing the escalating demand for transparency in the pharmaceutical and regulatory landscape. In the modern era, there is a growing expectation from the public and various stakeholders to understand the basis of regulatory decisions concerning medicinal products. By acknowledging and responding to this demand, the policy establishes a commitment to openness and accountability. This objective ensures that regulatory decisions are not only transparent but also founded on robust clinical evidence, aligning regulatory practices with the evolving expectations of an informed and engaged society.

The scope and application of EMA Policy 70

Looking at what’s covered by EMA Policy 70, it navigates the disclosure of clinical data, prioritizing transparency while safeguarding individual privacy. The five key areas include:

·       Centralized marketing authorization procedure

The scope includes clinical reports and individual patient data (IPD). These are essential elements under the centralized marketing authorization procedure, forming the evidence needed for regulatory decisions.

·       Clinical data components

EMA Policy 70 explicitly applies to clinical data submitted for medicines seeking EU approval, ensuring consistency and thorough scrutiny in the centralized process.

·       Publication requirements and timeline

Sponsors must publish anonymized versions of clinical study reports and submission documents after January 1, 2015, reflecting a commitment to a more transparent regulatory landscape.

·       Anonymization for privacy protection

The policy mandates meticulous anonymization to prevent any identifying details of individuals from showing in reports and documents, striking a balance between clarity and confidentiality.

·       Balancing transparency and privacy

The publication timeline and anonymization process demonstrate the policy's commitment to balance, ensuring public access to data without compromising research integrity or violating contributor rights.

The Impact of EMA Policy 70

The introduction of EMA Policy 70 marked a pivotal moment for a new era of data transparency in healthcare. By making clinical study data publicly accessible, the policy empowers researchers, healthcare professionals and members of the public to review and analyze clinical information with ease. This transparency has proven transformative, uncovering potential safety concerns and triggering further research to inform medical advancements.

EMA Policy 70 goes beyond transparency; it cultivates a collaborative environment where shared knowledge becomes a driving force for societal well-being. The policy fosters public scrutiny, ensuring an oversight that extends beyond regulatory boundaries. This collaborative spirit not only promotes transparency but actively contributes to a culture of continuous improvement in healthcare practices. In essence, EMA Policy 70 guides stakeholders towards a future where openness and collective knowledge propel positive change in the world of medicine.

EMA Policy 70 vs Policy 0043

It's important to note that EMA Policy 70 does not replace the existing Policy 0043 – the policy on access to documents (related to medicinal products for human and veterinary use). This older policy, in effect since December 2010, allows any medical or legal personnel to request access to documents independently of the publication process established by EMA Policy 70.

The coexistence of these policies highlights the multifaceted approach the EMA takes towards transparency, providing multiple avenues for accessing information.

What EMA policy means for the future

EMA Policy 70 is a pivotal step towards unlocking transparency in the field of medicine. By championing the principles of public health protection, transparency and stakeholder satisfaction, the policy establishes a foundation for a more informed and empowered society.

As we navigate the intricate landscape of medical data, it is imperative for stakeholders, including the general public, to be aware of and engage with EMA Policy 70. By understanding the policy and its implications, we contribute to the ongoing dialogue around data transparency, actively participating in shaping the future of healthcare.

EMA Policy 70 webinar

Discover how to unlock efficient redaction and transparency processes in line with EMA policy 70.

Watch now